> > > 【スタッフ紹介】市原 英基

【スタッフ紹介】市原 英基

【卒業年】 平成13年

【学位取得】平成22年

【専門領域】
呼吸器内科学、腫瘍内科学、緩和医療学

【資格】
がん薬物療法専門医(日本臨床腫瘍学会),緩和医療専門医(日本緩和医療学会),呼吸器専門医(日本呼吸器学会),認定内科医(日本内科学会)・総合内科専門医(日本内科学会),がん治療認定医(がん治療認定医機構)

【所属学会】
日本内科学会,日本呼吸器学会,日本臨床腫瘍学会,日本緩和医療学会,日本癌治療学会,日本肺癌学会,日本呼吸器内視鏡学会

【略歴】
平成13年 4月  岡山大学医学部附属病院 第二内科入局
平成13年 5月  岡山大学医学部附属病院 第二内科医員 (研修医)
平成13年 6月  神戸市立医療センター中央市民病院 内科研修医
平成15年 6月  神戸市立医療センター西市民病院 呼吸器内科専攻医
平成17年 6月  岡山大学医学部・歯学部附属病院 第二内科 医員
平成21年 4月  岡山大学大学院医歯薬学総合研究科(緩和医療学講座)助教
平成23年 4月  岡山大学大学院医歯薬学総合研究科(緩和医療学講座)講師
平成25年 4月  岡山大学病院 腫瘍センター 助教  研
平成25年 7月  Vanderbilt-Ingram Cancer Center Research Fellow
平成28年 2月  岡山大学大学院医歯薬学総合研究科 血液腫瘍呼吸器内科学 助教
平成29年 4月  岡山大学病院 呼吸器・アレルギー内科 助教

【一言】
患者さんと一緒に泣いて笑える医療者でありたいと思っています

【研究テーマ】
肺癌の分子標的治療

【主な業績】

最近の業績(Pubmedへのリンク)

1. Kuyama S, Ochi N, Bessho A, Hotta K, Ikeda G, Kishino D, Kubo T, Harada D, Fujimoto N, Nakanishi M, Umeno T, Okada T, Chikamori K, Yamagishi T, Ohashi K, Ichihara E, Takigawa N, Tanimoto M, Kiura K. A Phase II Trial of Carboplatin plus S-1 for Elderly Patients with Advanced Non-small-cell Lung Cancer with Wild-type Epidermal Growth Factor Receptor: The Okayama Lung Cancer Study Group Trial 1202. Lung Cancer 2017 [Epub ahead of print]

2. Otsubo K, Kishimoto J, Kenmotsu H, Minegishi Y, Ichihara E, Shiraki A, Kato T, Atagi S, Horinouchi H, Ando M, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakanishi Y, Okamoto I.Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced NoneSmall-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clin Lung Cancer. 2017[Epub ahead of print]

3. Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, Stanchina E, McEwen R, Ladanyi M, Cross D, PaoW, Lovly CM. SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer Cancer Res. 2017;77:2990-3000.

4. Higo H, Kurosaki T, Ichihara E, Kubo T, Miyoshi K, Otani S, Sugimoto S, Yamane M, Miyahara N, Kiura K, Miyoshi S, Oto T. Clinical characteristics of Japanese candidates for lung transplant due to interstitial lung disease and risk factors for early death while on the waiting list. Respir Investig. 2017;55:264-269.

5. Watanabe H, Ichihara E, Kano H, Ninomiya K, Tanimoto M, Kiura K. Congestive heart failure during osimertinib treatment for EGFR-mutant NSCLC. Intern Med. 2017;56:2195-2197.

6. Kudo K, Ohashi K, Makimoto G, Higo H, Kato Y, Kayatani H, Kurata Y, Takami Y, Minami D, Ninomiya T, Kubo T, Ichihara E, Sato A, Hotta K, Yoshino T, Tanimoto M, Kiura K. Triplet therapy with afatinib, cetuximab and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo. Mol Oncol. 2017 ;11:670-681.

7. Minami D, Takigawa N, Kano H, Ninomiya T, Kubo T, Ichihara E, Ohashi K, Sato A, Hotta K, Tabata M, Tanimoto M, Kiura K. Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. Jpn J Clin Oncol. 2017;47:434-437.

8. 狩野 裕久, 市原 英基, 南 大輔, 妹尾 賢, 西井 和也, 秦 雄介, 渡邉 洋美, 谷本 光音, 木浦 勝行. EBUS-TBNAで診断した歯肉癌の区域気管支周囲リンパ節転移 気管支学 Vol. 39 (2017) No. 2 p. 142-145

9. Ninomiya K, Ichihara E, Hotta K, Sone N, Murakami T, Harada D, Oze I, Kubo T, Tanaka H, Kuyama S, Kishino D, Bessho A, Harita S, Katsui K, Tanimoto M, Kiura K. Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. Clin Lung Cancer. 2017;18:245-249.

10. Oda N, Hotta K, Yoshioka H, Kudo K, Ichihara E, Kato Y, Ninomiya K, Minami D, Ninomiya T, Kubo T, Ohashi K, Sato A, Takigawa N, Tabata M, Tanimoto M, Kiura K. Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol. 2016;78:941-947.

11. Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E (Co-first author), Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM. EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov. 2016;6:601-11.

12. Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, Ichikawa H, Inoue M, Takata I, Shibayama T, Kuyama S, Sugimoto K, Harada D, Harita S, Sendo T, Tanimoto M, Kiura K. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). Clin Lung Cancer. 2016;17:602-605.

13. Osawa M, Ohashi K, Kubo T, Ichihara E, Takata S, Takigawa N, Takata M, Tanimoto M, Kiura K. Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation. Acta Med Okayama. 2016;70:243-53.

14. Oda N, Ichihara E, Hotta K, Ninomiya K, Ninomiya T, Kubo T, Minami D, Murakami T, Yokoyama T, Harada D, Kuyama S, Ichikawa H, Inoue K, Kishino D, Inoue M, Takigawa N, Shibayama T, Harita S, Tanimoto M, Kiura K. Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. Clin Lung Cancer. 2017;18:241-244.

15. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21:1038-47.

16. Ichihara E, Hotta K, Kiura K. Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015;10:e79.

17. Ichihara E, Lovly CM. Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. Cancer Discov. 2015;5:694-6.

18. Ninomiya K, Hotta K, Hisamoto-Sato A, Ichihara E, Gotoda H, Morichika D, Tamura T, Kayatani H, Minami D, Kubo T, Tabata M, Tanimoto M, Kiura K. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol. 2016;21:81-7.

19. Kudo K, Hotta K, Ichihara E, Yoshioka H, Kunimasa K, Tsubouchi K, Iwasaku M, Kato Y, Oze I, Takigawa N, Tanimoto M, Kiura K. Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer Chemother Pharmacol. 2015;76:251-6.

20. Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O’Brien EL, Barnes CH, Brown H, Smith PD, Dry JR, Beran G, Thress KS, Dougherty B, Pao W, Cross DA. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res. 2015;75:2489-500.

21. Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol. 2015;10:486-91.

22. Isozaki H, Yasugi M, Takigawa N, Hotta K, Ichihara E, Taniguchi A, Toyooka S, Hashida S, Sendo T, Tanimoto M, Kiura K. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene. Jpn J Clin Oncol. 2014;44:963-8.

23. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-61.

24. Yasugi M, Takigawa N, Ochi N, Ohashi K, Harada D, Ninomiya T, Murakami T, Honda Y, Ichihara E, Tanimoto M, Kiura K. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. Exp Cell Res. 2014;326:201-9.

25. Kato Y, Hotta K, Takigawa N, Nogami N, Kozuki T, Sato A, Ichihara E, Kudo K, Oze I, Tabata M, Shinkai T, Tanimoto M, Kiura K. Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol. 2014;73:943-50.

26. Ochi N, Takigawa N, Harada D, Yasugi M, Ichihara E, Hotta K, Tabata M, Tanimoto M, Kiura K. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Exp Cell Res. 2014;322:168-77.

27. Murakami T, Takigawa N, Ninomiya T, Ochi N, Yasugi M, Honda Y, Kubo T, Ichihara E, Hotta K, Tanimoto M, Kiura K. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. Lung Cancer. 2014;83:30-6.

28. Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, Yanase-Nakamura K, Tanaka H, Kato Y, Tabata M, Tanimoto M, Kiura K. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol. 2013;43:1115-23.

29. Hayakawa H, Ichihara E, Ohashi K, Ninomiya T, Yasugi M, Takata S, Sakai K, Matsumoto K, Takigawa N, Tanimoto M, Kiura K. Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model. Cancer Sci. 2013;104:1440-6.

30. Minami D, Takigawa N, Hayakawa H, Mizuta M, Kudo K, Uchida K, Ichihara E, Sato A, Hotta K, Tabata M, Tanimoto M, Kiura K. Usefulness of endobronchial ultrasound-guided transbronchial needle aspiration in distinguishing sarcoidosis from recurrent cancer in patients with lymphadenopathy after surgery. Jpn J Clin Oncol. 2013;43:1110-4.

31. Ichihara E, Hotta K, Takigawa N, Kudo K, Kato Y, Honda Y, Hayakawa H, Minami D, Sato A, Tabata M, Tanimoto M, Kiura K. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer. 2013;81:435-9.

32. Saito K, Takigawa N, Ohtani N, Iioka H, Tomita Y, Ueda R, Fukuoka J, Kuwahara K, Ichihara E, Kiura K, Kondo E. Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers. Mol Cancer Ther. 2013;12:1616-28.

33. Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, Tsukuda K, Takigawa N, Kiura K, Gazdar AF, Lam WL, Miyoshi S. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 2013;73:3051-61.

34. Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, Honda Y, Kubo T, Minami D, Kudo K, Tanimoto M, Kiura K. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013;12:589-97.

35. Kudo K, Ichihara E, Hisamoto A, Hotta K, Miyahara N, Tanimoto Y, Akagi S, Kato K, Tanimoto M, Kiura K. A definite case of (L)-carbocisteine-induced pneumonia with CATCH22 syndrome. Intern Med. 2013;52:97-100.

36. Takeda H, Takigawa N, Ohashi K, Minami D, Kataoka I, Ichihara E, Ochi N, Tanimoto M, Kiura K. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res. 2013;319:417-23.

37. Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, Hisamoto A, Hotta K, Tanimoto M, Kiura K. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res. 2013;11:140-8.

38. Hotta K, Suzuki E, Di Maio M, Chiodini P, Fujiwara Y, Takigawa N, Ichihara E, Reck M, Manegold C, Pilz L, Hisamoto-Sato A, Tabata M, Tanimoto M, Shepherd FA, Kiura K. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer. 2013;79:20-6.

39. Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, Ichihara E, Yamane H, Tanimoto M, Kiura K. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Sci. 2013;104:78-84.

40. 柚木三由起, 馬場華奈己, 高下典子, 市原英基, 松永尚, 野上浩實, 松岡順治. 岡山県における電話アンケート調査を基にした 緩和ケア認知度の経年的変化 ─野の花プロジェクトによる一般県民への緩和ケア啓発活動の開始前後での検討─Palliative Care Research 2013; 8(1): 101-16

41. Ochi N, Hotta K, Takigawa N, Oze I, Fujiwara Y, Ichihara E, Hisamoto A, Tabata M, Tanimoto M, Kiura K. Treatment-Related Death in Patients with Small-Cell Lung Cancer in Phase III Trials over the Last Two Decades. PLoS One. 2012;7:e42798.

42. Ozaki S, Takigawa N, Ichihara E, Hotta K, Oze I, Kurimoto E, Fushimi S, Ogino T, Tabata M, Tanimoto M, Kiura K. Favorable response of heavily treated wilms’ tumor to Paclitaxel and Carboplatin. Onkologie. 2012;35:283-6.

43. Fujii M, Hotta K, Takigawa N, Hisamoto A, Ichihara E, Tabata M, Tanimoto M, Kiura K. Influence of the timing of tumor regression after the initiation of chemoradiotherapy on prognosis in patients with limited-disease small-cell lung cancer achieving objective response. Lung Cancer. 2012;78:107-11.

44. Harada D, Takigawa N, Ochi N, Ninomiya T, Yasugi M, Kubo T, Takeda H, Ichihara E, Ohashi K, Takata S, Tanimoto M, Kiura K. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. Cancer Sci. 2012;103:1795-802.

45. Kudo K, Ichihara E, Hisamoto A, Hotta K, Ichimura K, Tanimoto Y, Tabata M, Takigawa N, Tanimoto M, Kiura K. Two cases of adult Langerhans cell histiocytosis treated with systemic chemotherapy. Nihon Naika Gakkai Zasshi. 2012;101:1386-8.

46. Nogami N, Hotta K, Segawa Y, Takigawa N, Hosokawa S, Oze I, Fujii M, Ichihara E, Shibayama T, Tada A, Hamada N, Uno M, Tamaoki A, Kuyama S, Ikeda G, Osawa M, Takata S, Tabata M, Tanimoto M, Kiura K. Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402. Acta Oncol. 2012;51:768-73.

47. Ichihara E, Kiura K, Tanimoto M. Targeting angiogenesis in cancer therapy. review Acta Med Okayama. 2011;65:353-62.

48. Ichihara E, Takigawa N, Kato K, Tanimoto Y, Yamadori I, Kiura K, Tanimoto M. Migrating ground glass opacities on computed tomography due to gravitation in a patient with pulmonary alveolar proteinosis. Chest Disease Reports 2011; 1:e2

49. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Hisamoto A, Ichihara E, Tabata M, Tanimoto M. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PLoS One. 2011;6:e26646.

50. Zhang D, Ochi N, Takigawa N, Tanimoto Y, Chen Y, Ichihara E, Hotta K, Tabata M, Tanimoto M, Kiura K. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer Lett. 2011;309:228-35.

51. Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, Shimizu K, Tanimoto M, Kiura K. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther. 2011;10:1720-7.

52. 南大輔、木浦勝行、瀧川奈義夫、堀田勝幸、村上斗司、高田三郎、谷口暁彦、小崎佐恵子、田中寿明、市原英基、田端雅弘、谷本光音. EBUS-TBNAでEGFR変異検出が可能であった全身状態不良高齢者肺腺癌の1症例 気管支学 2011;33:53-56

53. 市原英基、柚木三由起、藤原聡子、松永尚、堀田勝幸、瀧川奈義夫、田端雅弘、松岡順治、木浦勝行、谷本光音.がん化学療法におけるシスプラチン誘発遅発性嘔吐に対するアプピタントの有効性 Prog. Med. 2011;31:1787-91.

54. Ichihara E, Matsuoka J, Kiura K. Early palliative care in non-small-cell lung cancer. N Engl J Med. 2010;363:2263 ; author reply 2264-5.

55. Ohashi K, Takigawa N, Osawa M, Ichihara E, Takeda H, Kubo T, Hirano S, Yoshino T, Takata M, Tanimoto M, Kiura K. Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. Cancer Res. 2009;69:7088-95.

56. Ichihara E, Ohashi K, Takigawa N, Osawa M, Ogino A, Tanimoto M, Kiura K. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res. 2009;69:5091-8.

57. 市原英基、松岡順治、瀧川奈義夫、松崎孝、勝井邦彦、木浦勝行、谷本光音.多角的アプローチによりがん性疼痛のコントロールを得ることができた非小細胞肺癌の一例 岡山医学会雑誌 2009;121:173-5.

58. Ichihara E, Tabata M, Takigawa N, Sato Y, Kondo E, Aoe M, Kiura K, Tanimoto M. Synchronous pulmonary MALT lymphoma and pulmonary adenocarcinoma after metachronous gastric MALT lymphoma and gastric adenocarcinoma. J Thorac Oncol. 2008;3:1362-3.

59. Ichihara E, Kiura K, Takigawa N, Omori M, Aoe M, Tanimoto M, Date H. Pseudoprogression of lung cancer after concomitant chemoradiotherapy. Jpn J Clin Oncol. 2008;38:140-2.

60. Kubo T, Takigawa N, Tanimoto Y, Ichihara E, Tabata M, Miyahara N, Kanehiro A, Kiura K, Tanimoto M. Coinfection with Mycoplasma pneumoniae and Chlamydophila pneumoniae in a middle-aged adult. Nihon Kokyuki Gakkai Zasshi. 2007;45:808-11.

61. Ichihara E, Kaneko M, Fujii H, Ishihara K. Azygos vein aneurysm occurring simultaneously with hemoptysis. Nihon Kokyuki Gakkai Zasshi. 2007;45:479-82.

62. Kaneko M, Ishihara K, Hajiro T, Fujii H, Ichihara E. Characteristics of asthma patients who need repeated hospitalization; frequency of use of systemic corticosteroids, emergency and unscheduled hospital visits and habitual use of sleeping pills. Arerugi. 2007;56:477-84.

63. Takigawa N, Takeyama M, Kozuki T, Shibayama T, Hisamoto A, Kiura K, Tada A, Hotta K, Umemura S, Ohashi K, Fujiwara Y, Takata S, Ichihara E, Osawa M, Tabata M, Tanimoto M, Takahashi K. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells. Oncol Rep. 2007;17:983-7.

戻る